Idiopathic Hypersomnia

Zevra Joins Sleep Data Initiative As Founding Member

Zevra says data from its clinical program for its drug candidate to treat idiopathic hypersomnia will aid the development of treatments for rare sleep disorders through the platform.

Idiopathic Hypersomnia

WAKIX to Start Phase 3 Trial for Idiopathic Hypersomnia

Harmony Biosciences has initiated a phase 3 trial evaluating the efficacy and safety of pitolisant in adults with idiopathic hypersomnia.

Idiopathic Hypersomnia

Taking Back Control in Hypersomnia Disorders

A common concern in narcolepsy and idiopathic hypersomnia is a feeling of having little control over symptoms, which can lead to despair. But disorders of excessive sleepiness do have both medication and non-medication treatment approaches.

Jazz Pharmaceuticals Shares Results from Sleep Medicine Research & Therapy Development

Jun 9, 2021 | Idiopathic Hypersomnia, Narcolepsy, Prescription Drugs

Thirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.

Lack of Knowledge on Idiopathic Hypersomnia Often Leads to Misdiagnosis

Jun 8, 2021 | Curated, Idiopathic Hypersomnia

Idiopathic hypersomnia is a chronic neurologic sleep disorder that causes excessive daytime sleepiness even though a person can get adequate, or more typically, long amounts of sleep.

Jazz Pharmaceuticals Presents Phase 3 Results of Xywav in Idiopathic Hypersomnia

Apr 21, 2021 | Emerging Compounds, Idiopathic Hypersomnia, Prescription Drugs

The AAN presentation further quantifies the previously reported Phase 3 top-line results.

KemPharm Adds Potential Therapy for Idiopathic Hypersomnia to Its Product Pipeline

Dec 9, 2020 | Emerging Compounds, Idiopathic Hypersomnia

KemPharm is investigating “KP1077” as a potential treatment for idiopathic hypersomnia (IH), a sleep disorder of excessive sleepiness.

What Can PET Scans Teach Us About Narcolepsy?

Oct 21, 2020 | Idiopathic Hypersomnia, Imaging Studies, Narcolepsy

Emory University researchers find that functional imaging of the brain could shed light on the underlying disease states in hypersomnolence disorders.

FDA Fast Tracks Xywav for Idiopathic Hypersomnia

Oct 8, 2020 | Emerging Compounds, FDA, Idiopathic Hypersomnia

“There is significant need for greater awareness of idiopathic hypersomnia, which can severely impact a person’s daily life, and can often be misdiagnosed or undiagnosed over a substantial period of time.”

Hypersomnia Foundation Chooses Researcher Whose Work Will Focus on Inflammation’s Role in Excessive Daytime Sleepiness for Its First Research Award

Jun 24, 2019 | Hypersomnias, Idiopathic Hypersomnia, Narcolepsy, Prevailing Attitudes

The Hypersomnia Foundation, a nonprofit patient advocacy group dedicated to improving the lives of people with idiopathic hypersomnia and other rare sleep disorders, has chosen the first recipient of its new Research Award...

Retrospective Study Finds Increase in Narcolepsy and Idiopathic Hypersomnia Prevalence

Dec 30, 2018 | Idiopathic Hypersomnia, Narcolepsy

Over 4 years, narcolepsy prevalence in claims data increased 13.8% and IH prevalence 33.8%. By...

Machine-Learning Models Could Help with Hypersomnia Differential Diagnosis

Dec 17, 2018 | AI & Machine Learning, Idiopathic Hypersomnia, Narcolepsy

Researchers input MSLT and preceding PSG data, then report on the results. By Yoona Ha In recent...

New EEG Insights Offer Window into Hypersomnia Differential Diagnosis

Dec 12, 2018 | Idiopathic Hypersomnia, MSLT, MWT & Other Studies, Narcolepsy

Researchers investigate how timing and density of EEG segments differ among patients with...

Jazz Pharmaceuticals Enrolls First Patient in Phase 3 Clinical Trial Evaluating JZP-258 for Idiopathic Hypersomnia

Nov 30, 2018 | Idiopathic Hypersomnia, Narcolepsy, Prescription Drugs

Jazz Pharmaceuticals plc has enrolled the first patient in a phase 3 clinical trial evaluating the efficacy and safety of JZP-258 for the treatment of idiopathic hypersomnia. JZP-258 is an investigational oxybate mixed-salts...

Researchers Get Closer to Real Life Biomarker to Differentiate Hypersomnias

Apr 27, 2018 | Circadian & Sleep Biomarkers, Hypersomnias, Idiopathic Hypersomnia, MSLT, MWT & Other Studies, Narcolepsy

Narcolepsy type 1 is distinct from other hypersomnias in several ways. People diagnosed with it must have sleepiness and either objectively low levels orexin or cataplexy and a positive multiple sleep latency test.